Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia, Год журнала: 2025, Номер 11(1)

Опубликована: Апрель 3, 2025

Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET PRESCIENT research networks, Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Ascertainment Outcome Measures Team aimed to establish a harmonized assessment protocol across these two networks define criteria primary secondary endpoints. addition developing protocol, goals this aspect AMP SCZ project were: (1) implement monitor training, participants, assessments; (2) provide expert input Psychosis Risk Evaluation, Data Integration Computational Technologies: Processing, Analysis, Coordination Center (PREDICT-DPACC) for data collection, quality control, preparation analysis measures; (3) ongoing support analysis, reporting data. This paper describes endpoints outcomes, rationale selection measures, extensive training staff, (4) measures study which includes several sites where English is not native language; (5) measure stability over time in observational comparing ratings at baseline 2-month follow up. Watch Dr. Jean Addington discuss her work article: https://vimeo.com/1040425281 .

Язык: Английский

---

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Schizophrenia, Год журнала: 2025, Номер 11(1)

Опубликована: Март 24, 2025

Cognitive impairment occurs at higher rates in individuals clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance multivariate prediction models of transition psychosis. Such is considered a core biomarker schizophrenia. Thus, cognition key domain measured the Accelerating Medicines Partnership® program Schizophrenia (AMP SCZ initiative). The aim this paper describe rationale, processes, considerations, final harmonization cognitive battery used AMP across two data collection networks. This comprises tests general intellect specific domains. We estimate premorbid intelligence baseline measure current 2 years. Eight from Penn Computerized Neurocognitive Battery (PennCNB), which verbal learning memory, sensorimotor ability, attention, emotion recognition, working processing speed, visual motor speed are administered repeatedly baseline, four follow-up timepoints over

Язык: Английский

---

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia, Год журнала: 2025, Номер 11(1)

Опубликована: Апрель 2, 2025

Abstract Neuroimaging with MRI has been a frequent component of studies individuals at clinical high risk (CHR) for developing psychosis, goals understanding potential brain regions and systems impacted in the CHR state identifying prognostic or predictive biomarkers that can enhance our ability to forecast outcomes. To date, most involving are likely not sufficiently powered generate robust generalizable neuroimaging results. Here, we describe prospective, advanced, modern protocol was implemented complex multi-site, multi-vendor environment, as part large-scale Accelerating Medicines Partnership® Schizophrenia Program (AMP® SCZ), including rationale various choices. This includes T1- T2-weighted structural scans, resting-state fMRI, diffusion-weighted imaging collected two time points, approximately 2 months apart. We also present preliminary variance analyses several measures, such signal- contrast-to-noise ratio (SNR/CNR) spatial smoothness, provide quantitative data on relative percentages participant, site, platform (i.e., scanner model) variance. Site-related is generally small (typically <10%). For SNR/CNR measures from fMRI participant largest (as desired; 40–76%). However, diffusion there substantial platform-related (>55%) due differences hardware capabilities different scanners. Also, smoothness large inherent, difficult control, between vendors their acquisitions reconstructions. These results illustrate some factors will need be considered AMP SCZ data, which cohort date. Watch Dr. Harms discuss this article https://vimeo.com/1059777228?share=copy#t=0 .

Язык: Английский

---

Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia, Год журнала: 2025, Номер 11(1)

Опубликована: Апрель 3, 2025

Abstract Modern research management, particularly for publicly funded studies, assumes a data governance model in which grantees are considered stewards rather than owners of important sets. Thus, there is an expectation that collected shared as widely possible with the general community. This presents problems complex studies involve sensitive health information. The latter requires balancing participant privacy needs Here, we report on operation ecosystem crafted Accelerating Medicines Partnership® Schizophrenia project, international observational study young individuals at clinical high risk developing psychotic disorder. We review capture systems, dictionaries, organization principles, flow, security, quality control protocols, visualization, monitoring, and dissemination through NIMH Data Archive platform. focus interconnectedness these steps, where our goal to design seamless flow alignment FAIR (Findability, Accessibility, Interoperability, Reusability) principles while local regulatory ethical considerations. process-oriented approach leverages automated pipelines enhance quality, speed, collaboration, underscoring project’s contribution advancing practices involving multisite mental conditions. An feature data’s close-to-real-time assessment (QA) (QC). QA/QC makes it subject redo testing session, well facilitate course corrections prevent repeating errors future acquisition. Watch Dr. Sylvain Bouix discuss his work this article: https://vimeo.com/1025555648 .

Язык: Английский

---

Suggestions on early psychosis: towards a new psychopathology?

Опубликована: Март 5, 2025

In recent years, mental health professionals have diffusely treated “early psychosis” (EP), an unspecified clinical condition characterized by the first manifestation of psychotic symptoms (especially hallucinations, delusions, and disorganized speech), including attenuated prodromal ones. This term is currently used for provisional diagnosis, with detailed categorical definitions pending. The EP immediately recalls its antecedents symptoms, leading us back to early detection identification “At-Risk Mental States” (ARMSs) psychosis. Although helpful treatments reducing duration untreated psychosis, conceptualization remains unclear, especially in psychopathological trajectories. Does refer onset functioning decline or instance psychological distress simply contact healthcare services? There a “nebula” which multiplicity conditions may exist, often undefined unspecified, sinking their roots very patient’s life. this paper, we discuss some suggestions better understand complexity. Moreover, based on common experiences, hypotheses development change current methodological approach intervention will be advanced. Finally, different definition “normality” (also taking into account modern digital revolution, instability life phases, increasingly poor confidence future) proposed as element characterizing new young generations potential, broader interpretation conceptualization.

Язык: Английский

---

Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Март 17, 2025

Abstract Systemic lupus erythematosus (SLE) is a chronic inflammatory illness with heterogeneous clinical manifestations covering multiple organs. Diversified types of medications have been shown effective for alleviating SLE syndromes, ranging from cytokines, antibodies, hormones, molecular inhibitors or antagonists, to cell transfusion. Drugs developed treating other diseases may benefit patients, and agents established as therapeutics be SLE-inductive. Complexities regarding render it essential urgent identify the mechanisms-of-action pivotal signaling axis driving pathogenesis, establish innovative SLE-targeting approaches desirable therapeutic outcome safety. After introducing research history its epidemiology, we categorized primary determinants pathogenesis by their mechanisms; combed through current knowledge on diagnosis grouped them disease onset, activity comorbidity; introduced genetic, epigenetic, hormonal environmental factors predisposing SLE; comprehensively preventive strategies available according functioning mechanisms. In summary, proposed three mechanisms determinant roles initiation progression, i.e., attenuating immune system, restoring cytokine microenvironment homeostasis, rescuing impaired debris clearance machinery; provided updated insights understandings diagnosis, prevention therapeutics, which open an avenue in fields management.

Язык: Английский

---

Increasing conceptual clarity and confounders identification: a pragmatic way to enhance prognostic precision in ENIGMA clinical high risk for psychosis (CHR-P)

Molecular Psychiatry, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Язык: Английский

---

Variability Rather Than Means? Harnessing the Adversary to Advance Precision Psychiatry

American Journal of Psychiatry, Год журнала: 2025, Номер 182(4), С. 326 - 328

Опубликована: Апрель 1, 2025

Язык: Английский

---

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia, Год журнала: 2025, Номер 11(1)

Опубликована: Апрель 3, 2025

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. assessments include domains similar to those acquired previous CHR studies along with novel that collected longitudinally period 2 years. In parallel the data acquisition, multidisciplinary teams experts have been working formulate analysis strategy AMP SCZ project. Here, we describe key principles analysis. primary aim is use baseline multimodal biomarkers predict endpoints individuals. These defined study as transition (i.e., conversion), remission from syndrome, persistent syndrome (non-conversion/non-remission) obtained one year two years after assessment. secondary longitudinal all time points identify trajectories differentiate subgroups design plan informed by reviewing legacy analytic approaches international studies. addition, consider properties newly distinct available data. Legacy used assist pipeline building, perform benchmark experiments, quantify concepts make decisions meant overcome challenges encountered We present project, mitigation strategies address related plan, provide rationales decisions, examples how support Watch Prof. Ofer Pasternak discuss his work this article: https://vimeo.com/1023394132?share=copy#t=0 .

Язык: Английский

---

Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia, Год журнала: 2025, Номер 11(1)

Опубликована: Апрель 7, 2025

Язык: Английский

---